FORM PTO-139 (REV 7-05)	U.S. DEPARTMENT OF COMMERCE PATER	NT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER							
(KEY 1413)	TRANSMITTAL LETTER TO T		PP019155.0004							
	DESIGNATED/ELECTED OFF	•	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)							
	CONCERNING A FILING UND	10/525,535								
INTERNATIONAL APPLICATION NO.		INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
PCT/US2003/026612		25 August 2003	23 August 2002							
TITLE OF IN										
COMPOSITIONS AND METHODS OF THERAPY FOR CANCERS CHARACTERIZED BY EXPRESSION OF THE TUMOR-ASSOCIATED ANTIGEN MN/CA IX										
TOWOK-ASSOCIATED ANTIGEN WIWCA IA										
APPLICANT(S) FOR DO/EO/US										
WONG, Justin; WINTER, Jill; LALEHZADEH, Guita; and WARNE, Robert										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
1.	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.									
2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.									
3.	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). This submission must include									
	items (5), (6), (9) and (21) indicated below.									
4.	The US has been elected (Article 31).									
5. 🗌	A copy of the International Applic	A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
		o (required only if not communicated by the Int	ernational Bureau).							
	 b.									
6.		the International Application as filed (35 U.S.C	. 371(c)(2)).							
	a. is attached heret b. has been previou	o. usly submitted under 35 U.S.C. 154(d)(4).								
7. 🗆	·	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))								
,, <u> </u>		••								
	 a.									
		ade; however, the time limit for making such are lade and will not be made.	mendments has NOT expired.							
										
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).								
9. 🛛	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).									
10.	An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).									
Items 11	i. To 20. below concern document(s) or information included:								
11. 🔲	An Information Disclosure Statem	nent under 37 C.F.R. 1.97 and 1.98.								
12. 🔲	An assignment document for reco	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
13. 🔲	A FIRST preliminary amendment	A FIRST preliminary amendment.								
	A SECOND or SUBSEQUENT p	A SECOND or SUBSEQUENT preliminary amendment.								
14.	An Application Data Sheet under 37 CFR 1.76									
15. 🔲	A substitute specification.	•								
16. 🛛	A power of attorney and/or change of address letter.									
17. 🛛	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825 (electronic file									
18. 🗌	submission). A second copy of the published in	nternational application under 35 U.S.C. 154(d)(4).							
19.	A second copy of the published international application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).									
20.	Other items or information: Statement in Support of Filing a Sequence Listing (1 pg); concurrently filed Petition to Revive under 37									
20.		(authorization to charge deposit account 16-060)								

U.S. APPLICATION NO. (If known 10/525,535	INTERNATIONAL APPI PCT/US2003/026612			ATTORNEY'S DOCKET I PP019155.0004	TORNEY'S DOCKET NUMBER PP019155.0004				
☐ The following fees have bee	en submitted:	Calculations	PTO USE ONLY						
21. Basic national fee (37 CFR 1.492(a))									
22. Examination fee (37 CFR 1.492 (c))									
(If the written opinion prepared by ISA/US or the international preliminary examination report									
prepared by the IPEA/US inc									
All other situations			,						
23. Search fee (37 CFR	` ''								
If the written opinion of the prepared by IPEA/US indicates	ates all claims satisfy								
Search fee (37 CFR 1.445(a)									
to the USPTO as an Internat	•								
International Search Report	• • •								
or previously communicated	-								
All other situations									
	ΓAL OF 21, 22 and								
Additional fee for specifi									
sequence listing in complian an electronic medium) (37 C		21(c) or (e) or comput	er program li	sting filed in					
The fee is \$250.00 for each a	•	of nanar or function 41	eraof						
Total Sheets Ext		of each additional 50		Rate					
		(round up to a whole r		Rate					
- 100 = /50	==			x \$250					
Surcharge of \$130.00 for fur									
declaration later the date of		\$ 130.00							
CLAIMS Tetal Claims	NUMBER FILED 0 -20 =	NUMBER EXTRA	RATE			<u> </u>			
Total Claims Independent Claims	0 -20 =	0	X \$ 50.00 X \$200.00						
MULTIPLE DEPENDENT CL.	•	1 * 1	+ \$360.00						
	TOTAI	\$130.00							
Applicant claims small of	entity status. See 37	CFR 1.27. The fees	indicated abo	ve are					
reduced by 1/2.						,			
Processing fee of \$130.00 fo	Ci-lain		SUBTOTAL		\$130.00				
earliest claimed priority date			nan 30 monu	ns from the					
Carriest claimed priority date	0 (37 611(1.1)2(1)).	\$130.00							
Fee for recording the enclos	TOTAL NATIONAL FEE = \$130.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be								
accompanied by an appropri									
		TOTAL FEES ENCLO	OSED =		\$130.00				
			Amount to be Refunded	\$					
		Amount to be	\$						
			Charged						
 a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. 16-0605 in the amount of \$130.00 to cover the above fee. 									
. =						eposit Account No. 16-0605.			
Note: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the									
application to pending status. SEND ALL CORRESPONDENCE TO:									
Lisa E. Alexander, Registrat			ED USING THE EFS-V						
NOVARTIS VACCINES A	ND DIAGNOSTIC	TILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK DFFICE ON March 6, 2007.							
Corporate Intellectual Prope	erty R338								
P.O. Box 8097 Emeryville, CA 94662-809	7118								
Customer Number 27476	7 03								
1	_								
herry 1, H	ren	<u>, </u>							
Leslie T. Henry Agent for Applicants	0		1						
REGISTRATION NUMBER	R 45,714								
I DC AI 02/202505571									